In the PARADIGM-HF trial [62], the use of angiotensin receptor-neprilysin inhibitor in HFrEF patients induced a 30% decline in NT-proBNP level after the run-in period of 4–6 weeks, and the reduction was associated with the change in cardiovascular mortality and HF hospitalization rate. This evidence concerns the gene MME and hydrops fetalis.